Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.
It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS or SPMS will also be communicated, the company said... Read More - http://www.ms-uk.org/index.cfm/gilenya
Novartis To Present New Data On Multiple Sclerosis Treatment
Novartis To Present New Data On Multiple Sclerosis Treatment
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1845 Views
-
Last post by frodo
-
- 1 Replies
- 1864 Views
-
Last post by frodo
-
- 0 Replies
- 1720 Views
-
Last post by frodo
-
- 0 Replies
- 1667 Views
-
Last post by frodo
-
- 0 Replies
- 1337 Views
-
Last post by frodo
-
- 0 Replies
- 3683 Views
-
Last post by frodo
-
- 0 Replies
- 2298 Views
-
Last post by frodo
-
- 0 Replies
- 1926 Views
-
Last post by NHE
-
- 0 Replies
- 865 Views
-
Last post by maggieMSOC